113 related articles for article (PubMed ID: 2743591)
1. Plasma free dopamine in human hypertension.
Miura Y; Takahashi M; Sano N; Ohzeki T; Meguro Y; Sugawara T; Noshiro T; Watanabe H; Shimizu K; Abe K
Clin Exp Hypertens A; 1989; 11 Suppl 1():227-36. PubMed ID: 2743591
[TBL] [Abstract][Full Text] [Related]
2. Plasma free dopamine: physiological variability and pathophysiological significance.
Miura Y; Watanabe T; Noshiro T; Shimizu K; Kusakari T; Akama H; Shibukawa S; Miura W; Ohzeki T; Takahashi M
Hypertens Res; 1995 Jun; 18 Suppl 1():S65-72. PubMed ID: 8529077
[TBL] [Abstract][Full Text] [Related]
3. [Plasma dopamine concentrations in various types of hypertension].
Takahashi M; Miura Y; Sano N; Kimura S; Toriyabe S; Ishizuka Y; Ohashi H; Noshiro T; Sugawara T; Watanabe H
Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):713-23. PubMed ID: 3758430
[TBL] [Abstract][Full Text] [Related]
4. [Catecholamines in hypertension: studies on plasma free dopamine concentration in patients with various types of hypertension].
Miura Y
Rinsho Byori; 1989 Jan; 37(1):19-24. PubMed ID: 2724578
[No Abstract] [Full Text] [Related]
5. Dopamine and nonmodulating hypertension.
Williams GH; Gordon MS; Stuenkel CA; Conlin PR; Hollenberg NK
Am J Hypertens; 1990 Jun; 3(6 Pt 2):112S-115S. PubMed ID: 2383375
[TBL] [Abstract][Full Text] [Related]
6. [Effects of high sodium diet on dopaminergic mechanism in normal and hypertensive subjects].
Takahashi M; Miura Y; Sano N; Ohzeki T; Sugawara T; Noshiro T; Meguro Y; Watanabe H; Shimizu K; Hanew K
Nihon Naibunpi Gakkai Zasshi; 1988 Nov; 64(11):1157-68. PubMed ID: 3065095
[TBL] [Abstract][Full Text] [Related]
7. Physiological significance of plasma sulfoconjugated dopamine in patients with hypertension--clinical and experimental studies.
Yoshizumi M; Kitagawa T; Hori T; Katoh I; Houchi H; Ohuchi T; Oka M
Life Sci; 1996; 59(4):324-30. PubMed ID: 8761004
[TBL] [Abstract][Full Text] [Related]
8. Dopamine: an important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension.
Snider SR; Kuchel O
Endocr Rev; 1983; 4(3):291-309. PubMed ID: 6354703
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic modulation of salt sensitivity in patients with essential hypertension.
Shikuma R; Yoshimura M; Kambara S; Yamazaki H; Takashina R; Takahashi H; Takeda K; Ijichi H
Life Sci; 1986 Mar; 38(10):915-21. PubMed ID: 3951317
[TBL] [Abstract][Full Text] [Related]
10. Decreased central dopaminergic activity in essential hypertension.
Os I; Kjeldsen SE; Westheim A; Aakesson I; Norman N; Enger E; Hjermann I; Eide I
J Hypertens; 1987 Apr; 5(2):191-7. PubMed ID: 3611768
[TBL] [Abstract][Full Text] [Related]
11. Central dopaminergic control of prolactin in essential hypertension.
Os I; Kjeldsen SE; Westheim A; Normann N; Aakesson I; Hjermann I; Eide I
Acta Med Scand Suppl; 1986; 714():113-7. PubMed ID: 3472433
[TBL] [Abstract][Full Text] [Related]
12. The role of dopamine in nonmodulating hypertension.
Gordon MS; Steunkel CA; Conlin PR; Hollenberg NK; Williams GH
J Clin Endocrinol Metab; 1989 Aug; 69(2):426-32. PubMed ID: 2753983
[TBL] [Abstract][Full Text] [Related]
13. Plasma free and sulfoconjugated dopamine in man: relationship to sympathetic activity, adrenal function and meals.
Eldrup E; Hagen C; Christensen NJ; Olgaard K
Dan Med Bull; 1988 Jun; 35(3):291-4. PubMed ID: 3168558
[TBL] [Abstract][Full Text] [Related]
14. [Physiological significance of plasma free and conjugated dopamine in healthy volunteers--with special reference to sympathetic nerve activity].
Nishimura M; Kikuchi K; Sato S; Sawai K; Yamaji I; Aoki K; Iimura O; Yamatodani A; Yamamoto T; Wada H
Nihon Naibunpi Gakkai Zasshi; 1988 Jun; 64(6):506-13. PubMed ID: 3208921
[TBL] [Abstract][Full Text] [Related]
15. Decreased peripheral dopaminergic activity in essential hypertension?
Kjeldsen SE; Flaaten B; Eide I; Helgeland A; Leren P; Fønstelien E
Scand J Clin Lab Invest; 1983 Feb; 43(1):15-20. PubMed ID: 6622964
[TBL] [Abstract][Full Text] [Related]
16. Effect of saline load and metoclopramide on the renal dopaminergic system in patients with heart failure and healthy controls.
Alvelos M; Ferreira A; Bettencourt P; Pimenta J; Azevedo A; Serrão P; Rocha-Gonçalves F; Soares-da-Silva P
J Cardiovasc Pharmacol; 2005 Mar; 45(3):197-203. PubMed ID: 15725943
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiological role of renal dopaminergic activity in patients with essential hypertension.
Iimura O; Yamaji I; Kikuchi K; Shibata S; Nishimura M; Nozawa A; Aoki K; Hasegawa T; Kobayakawa H; Komura H
Jpn Circ J; 1987 Oct; 51(10):1232-40. PubMed ID: 3323560
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic control of aldosterone secretion in hypertensive patients chronically treated with an angiotensin converting enzyme inhibitor.
Waeber B; Nussberger J; Schaller MD; Gomez HJ; Brunner HR
Horm Metab Res; 1986 Jan; 18(1):60-3. PubMed ID: 3005150
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous dopamine on blood pressure and plasma insulin in hypertensive patients.
Martin G; Forte P; Luchsinger A; Mendoza F; Urbina-Quintana A; Hernandez Pieretti O; Romero E; Velasco M
Eur J Clin Pharmacol; 1993; 45(6):503-5. PubMed ID: 8157035
[TBL] [Abstract][Full Text] [Related]
20. Decreased platelet-free dopamine and unchanged noradrenaline and adrenaline in essential hypertension.
Kjeldsen SE; Gjesdal K; Leren P; Eide IK
Thromb Haemost; 1988 Oct; 60(2):251-4. PubMed ID: 3217920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
